Brief: OSE Immunotherapeutics FY Net Loss Widens To EUR 16.8 Mln

Ose Immunotherapeutics SA

30/03/2022 17:44

March 30 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * SHARED POSITIVE FINAL PHASE 3 RESULTS FOR TEDOPI® IN
NON-SMALL
CELL LUNG CANCER (NSCLC) PATIENTS IN SECONDARY RESISTANCE AFTER
FAILURE WITH SECOND-LINE CHECKPOINT INHIBITOR TREATMENT.
    * RECEIVED AN EUR 8 MILLION MILESTONE PAYMENT UPON
INITIATION OF
EXPANSION PHASE OF PHASE 1 TRIAL OF ANTI-SIRPΑ BI 765063
(CD47/SIRPΑ PATHWAY) IN ADVANCED SOLID TUMOR PATIENTS BEING
CONDUCTED WITH PARTNER BOEHRINGER INGELHEIM, AFTER POSITIVE DOSE
ESCALATION RESULTS
    * RECEIVED A EUR 5 MILLION MILESTONE PAYMENT UPON INITIATION
OF A
PHASE 2 TRIAL WITH OSE-127/S95011 IN SJÖGREN'S SYNDROME WITH
PARTNER SERVIER, SPONSOR OF TRIAL.
    * RECEIVED A EUR 7 MILLION MILESTONE PAYMENT UPON SIGNATURE
OF A
LICENSE AGREEMENT WITH VELOXIS PHARMACEUTICALS INC. FOR FR104,
ANTI-CD28, IN TRANSPLANT INDICATIONS; AN ADDITIONAL EUR 5
MILLION MILESTONE PAYMENT WAS MADE IN EARLY 2022 UPON ACCEPTANCE
OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION OBTAINED IN U.S.
    * REPORTING A TOTAL OF EUR 26 MILLION TURNOVER LINKED TO
COMPANY'S
PHARMACEUTICAL PARTNERSHIPS AND EUR 33.6 MILLION AVAILABLE CASH
AS OF DECEMBER 31, 2021 VERSUS EUR 29.4 MILLION AS OF DECEMBER
31, 2020
    * FY RECURRING OPERATING LOSS EUR 16.6 MLN VS LOSS EUR 19
MLN YR
AGO
    * FY NET LOSS EUR 16.8 MLN VS LOSS EUR 16.5 MLN YR AGO

Source text for Eikon:  urn:newsml:reuters.com:*:nGNX3ybf4F
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 772 09 20;))